Dr. Austin Golia @AustinGolia_ID, PGY2 ID resident (2020-2021) in action at poster session discussing his research projects on Cef-Tazo vs. Cef-Avi for PsA infection; COVID-19 reinfection requiring re-tx. @IDWeek2022 @SIDPharm@BronxASP@MontefioreID@kecowman@PriyaNori
Very excited to see this published! Thank you @ASHE_Journal for helping us share insights that can help improve empiric antibiotic choices for our heme malignancy patients! #TxID#IDTwitter
New AMR Reads of the Week!
🐔Dr Jamie Umber evaluates evidence for AMR transmission between humans and chickens in Vietnam @jac_amr
💊@natalievestin explores @BronxASP's experience with an ASP-led outpatient COVID-19 therapeutics program @ASHE_Journal
https://t.co/6Iq9MXxVzJ
New AMR Reads of the Week!
🐔Dr Jamie Umber evaluates evidence for AMR transmission between humans and chickens in Vietnam @jac_amr
💊@natalievestin explores @BronxASP's experience with an ASP-led outpatient COVID-19 therapeutics program @ASHE_Journal
https://t.co/6Iq9MXxVzJ
Unfortunately, elevated initial PCT levels in hospitalized COVID-19 patients can mislead clinicians toward prescribing antibiotics when no co-infections are present
A new study 💥 @PriyaNori et Al #IDTwitter
https://t.co/PdvIFpYP9s
In this phase 3 trial, molnupiravir, a small-molecule antiviral, was studied in unvaccinated patients with less than 5 days of #COVID19 illness. By day 29, hospitalization for progression of Covid-19 was lower with molnupiravir. #IDTwitter https://t.co/lsKw1QaXhd